Interpatient variability in the pharmacokinetics of the HIV non‐nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and <i>CYP2B6</i> polymorphism

Abstract

Gender and race are important factors in determining interpatient variability in plasma efavirenz concentrations which were unaffected by the presence of the CYP2B6 C1459T polymorphism. Physicians should be particularly alert for signs of efavirenz-induced toxicity in females and non-Caucasian patients.